Companies / Australia
Peptech And EvoGenix To Merge
May 2007 | Company News AlertCreating a world class antibody powerhouse, the Australian biotechnology firms Peptech and EvoGenix are to merge in an AUD156mn (US$130mn) deal. BMI is expecting great things from the combined company given its state-of-the-art technology platform, lucrative revenue streams and promising pipeline of product candidates.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
